Following these revelations, the justice system opened several lines of investigation involving officials and entrepreneurs from the sector. In this context, the request for an interrogation now aims to determine if there was an attempt to hinder the judicial investigation or prevent access to the company's internal communications, a measure that could be key to reconstructing the decisions and links between the company's executives and the investigated contracts. Federal prosecutor Carlos Rívolo requested the interrogation of the head of Systems at Droguería Suizo Argentina S.A., Daniel Díaz, for having refused to reset the passwords of the company's executives, which prevented the Justice system from accessing the corporate emails required in the context of a judicial investigation. The proposal is made in a case stemming from the file that investigates alleged irregularities at the National Agency for Disability (ANDIS), as reported by the Argentine News Agency. The refusal of the head of the IT department would have blocked judicial access to the corporate emails of the company's executives, considered relevant evidence within the investigation. The file seeks to determine if there were maneuvers to obstruct access to information that could be key to the progress of the case. The case is part of a broader investigation that analyzes the link between Droguería Suizo Argentina and contracts carried out by ANDIS. The company belongs to the Kovalivker family, a business group that has controlled the firm for decades and is currently under judicial scrutiny for its involvement in operations linked to the public health system. Within this framework, Jonathan Simón Kovalivker appears, one of the company's main shareholders along with his father Eduardo and his brothers, who would have held a strategic position in the relationship between the pharmacy and the state agency. The ANDIS case began in 2025 after the dissemination of audios attributed to the then head of the agency, Diego Spagnuolo, which mentioned alleged irregularities in the hiring of medications and possible undue payments linked to supplier companies.
